AIM ImmunoTech EBIT

The latest EBIT for AIM is $-5.4M as of September 2026. That compares with $-15M in the prior-year period — up 64.5% year over year. That is below the Healthcare sector average of $1.9T. Investors often review this figure alongside AIM ImmunoTech's historical trend and sector peers before judging valuation or financial health.

Over the past year, AIM's EBIT moved from $-15M to $-5.4M — a 64.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in AIM ImmunoTech's operating scale or balance-sheet position.

Against Healthcare companies, AIM currently prints $-5.4M for EBIT, while the sector average sits near $1.9T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at AIM ImmunoTech's growth, margins, and balance sheet.

A EBIT figure of $-5.4M for AIM is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $1.9T. Explore the charts below for those layers of context.

After noting AIM's EBIT ($-5.4M), review year-over-year change from $-15M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.